Systemic Treatment with Fas-Blocking Peptide Attenuates Apoptosis in Brain Ischemia
Sungeun Chung,Yujong Yi,Irfan Ullah,Kunho Chung,Seongjun Park,Jaeyeoung Lim,Chaeyeon Kim,Seon-Hong Pyun,Minkyung Kim,Dokyoung Kim,Minhyung Lee,Taiyoun Rhim,Sang-Kyung Lee
DOI: https://doi.org/10.3390/ijms25010661
IF: 5.6
2024-01-05
International Journal of Molecular Sciences
Abstract:Apoptosis plays a crucial role in neuronal injury, with substantial evidence implicating Fas-mediated cell death as a key factor in ischemic strokes. To address this, inhibition of Fas-signaling has emerged as a promising strategy in preventing neuronal cell death and alleviating brain ischemia. However, the challenge of overcoming the blood–brain barrier (BBB) hampers the effective delivery of therapeutic drugs to the central nervous system (CNS). In this study, we employed a 30 amino acid-long leptin peptide to facilitate BBB penetration. By conjugating the leptin peptide with a Fas-blocking peptide (FBP) using polyethylene glycol (PEG), we achieved specific accumulation in the Fas-expressing infarction region of the brain following systemic administration. Notably, administration in leptin receptor-deficient db/db mice demonstrated that leptin facilitated the delivery of FBP peptide. We found that the systemic administration of leptin-PEG-FBP effectively inhibited Fas-mediated apoptosis in the ischemic region, resulting in a significant reduction of neuronal cell death, decreased infarct volumes, and accelerated recovery. Importantly, neither leptin nor PEG-FBP influenced apoptotic signaling in brain ischemia. Here, we demonstrate that the systemic delivery of leptin-PEG-FBP presents a promising and viable strategy for treating cerebral ischemic stroke. Our approach not only highlights the therapeutic potential but also emphasizes the importance of overcoming BBB challenges to advance treatments for neurological disorders.
biochemistry & molecular biology,chemistry, multidisciplinary